Myomo, Inc. (MYO)
| Market Cap | 32.85M -77.7% |
| Revenue (ttm) | 40.93M +25.7% |
| Net Income | -15.57M |
| EPS | -0.37 |
| Shares Out | 38.51M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 264,962 |
| Open | 0.8567 |
| Previous Close | 0.8774 |
| Day's Range | 0.8301 - 0.8613 |
| 52-Week Range | 0.6050 - 4.8700 |
| Beta | 1.39 |
| Analysts | Strong Buy |
| Price Target | 7.67 (+799.18%) |
| Earnings Date | May 7, 2026 |
About MYO
Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States, Germany, and internationally. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient’s weak or paralyzed arm to enable and improve functional activities of daily living. It also provides MyoPro 2 that includes control technology, configuration software and user interface, and pop-out battery for extended use of the bra... [Read more]
Financial Performance
In 2025, Myomo's revenue was $40.93 million, an increase of 25.73% compared to the previous year's $32.55 million. Losses were -$15.57 million, 151.9% more than in 2024.
Financial StatementsAnalyst Summary
According to 3 analysts, the average rating for MYO stock is "Strong Buy." The 12-month stock price target is $7.67, which is an increase of 799.18% from the latest price.
News
Myomo Announces Availability of MyoPro at Ottobock Care Clinics in the U.S.
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company and manufacturer of the MyoPro® powered arm brace, announces expanded access to the MyoPro dev...
Myomo to Report First Quarter 2026 Financial Results on May 7
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo Introduces Myomo Mobile App to Enhance Clinical Workflow and Patient Engagement
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company that offers increased functionality for people with neurological disorders and upper-limb para...
Myomo Appoints William J Febbo to its Board of Directors
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo Earnings Call Transcript: Q4 2025
Revenue grew 26% to $40.9M in 2025, with record Q4 orders and strong O&P and international growth. Recurring sources now make up 42% of Q4 revenue, and 2026 guidance targets $43–$46M revenue, higher gross margin, and halved cash burn.
Myomo Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo and Elevance Health Agree to Contract for Multi-State Network Participation
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo to Report Fourth Quarter 2025 Financial Results on March 9
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo Earnings Call Transcript: Q3 2025
Q3 2025 revenue rose 10% to $10.1M, driven by record international and O&P channel growth. Gross margin declined due to higher costs, but the patient pipeline expanded 32% year-over-year. Full-year guidance of $40–$42M was reiterated, with a focus on operating leverage and diversified revenue streams.
Myomo Reports Third Quarter 2025 Financial and Operating Results
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo to Report Third Quarter 2025 Financial Results on November 10
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo to Present at the H.C. Wainwright 27th Annual Global Investment Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo Earnings Call Transcript: Q2 2025
Q2 2025 revenue grew 28% year-over-year to $9.7M, but conversion rates and margins declined due to lower lead quality and higher costs. Cost-saving actions and a shift to TV advertising are underway, with full-year revenue now guided to $40–$42M, up 23–29%.
Myomo Reports Second Quarter 2025 Financial and Operating Results
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo to Report Second Quarter 2025 Financial Results on August 11
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo Transcript: Investor Day 2025
Management targets $100 million revenue by 2028, driven by direct billing, O&P, and international growth, with manufacturing and operational efficiencies supporting scale. Gross margin is targeted at 70–72%, and the O&P channel relaunch aims for $20 million revenue. Key risks include payer dynamics and channel adoption.
Myomo Provides Highlights of Today's Investor & Analyst Day Event
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo Reports First Quarter 2025 Financial and Operating Results
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo Earnings Call Transcript: Q1 2025
Q1 2025 saw 162% revenue growth to $9.8M, driven by Medicare and international sales, with gross margin up to 67.2%. The pipeline and O&P channel expanded, and full-year guidance of $50–$53M was reaffirmed, despite ongoing insurance and marketing challenges.
Myomo to Host Investor & Analyst Day Event on June 18, 2025
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo to Report First Quarter 2025 Financial Results on May 7
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo Launches the MyoPro® 2x
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO), a wearable medical robotics company that offers improved arm and hand function for individuals with upper-limb paralysis and neuro...
Myomo Transcript: 24th Annual Needham Virtual Healthcare Conference
Medicare reimbursement has unlocked a large U.S. market, driving record revenue and rapid growth. The company is expanding its O&P channel, investing in R&D, and expects 2025 revenue of $50–$53 million, with minimal tariff impact and strong leadership guiding its strategy.
Myomo Announces Upcoming Changes to its Board of Directors
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...
Myomo to Present at the 24th Annual Needham Virtual Healthcare Conference
BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable medical robotics company that offers increased functionality for those suffering from neurol...